[go: up one dir, main page]

WO2004006942A1 - Procede permettant de maintenir un transfert cellulaire direct - Google Patents

Procede permettant de maintenir un transfert cellulaire direct Download PDF

Info

Publication number
WO2004006942A1
WO2004006942A1 PCT/US2003/021421 US0321421W WO2004006942A1 WO 2004006942 A1 WO2004006942 A1 WO 2004006942A1 US 0321421 W US0321421 W US 0321421W WO 2004006942 A1 WO2004006942 A1 WO 2004006942A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
target area
plug member
therapeutic agent
introduction site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/021421
Other languages
English (en)
Inventor
Maria Palasis
James J. Barry
Arthur Rosenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Ltd Barbados
Boston Scientific Scimed Inc
Original Assignee
Boston Scientific Ltd Barbados
Scimed Life Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Scientific Ltd Barbados, Scimed Life Systems Inc filed Critical Boston Scientific Ltd Barbados
Priority to EP03764400A priority Critical patent/EP1523319A1/fr
Priority to AU2003251813A priority patent/AU2003251813A1/en
Publication of WO2004006942A1 publication Critical patent/WO2004006942A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Definitions

  • the present invention provides a method for sustaining the delivery of cells to a target
  • Direct cell delivery also referred to herein as “cellular transplantation” or “cellular graft”
  • cellular transplantation has been considered to increase the density of cells in the target area and therefore increase cell survival in tissue, as it is believed that cells must form clusters to survive in tissue.
  • cellular transplantation also referred to herein as "cellular transplantation” or "cellular graft”
  • scar tissue often forms in the target area separating the cellular graft from the target area.
  • invention provides a method for direct and efficient delivery of cells that increases the number of
  • the presently claimed method achieves these benefits, while also providing for inhibition of cell leakage from the introduction site of the target area.
  • the present invention provides a method for sustaining the delivery of cells to a target area within a mammalian body.
  • the method involves introducing cells through an introduction
  • the method further includes depositing at the introduction site, a plug member that contains a therapeutic agent that is released from the plug member to the target area.
  • the present invention provides another method for sustaining the delivery of cells to a
  • the method involves introducing cells through an introduction site of a target area and delivering the cells to the target area.
  • the method also includes applying an energy stimulus to the target area that promotes a wound-healing response in the target area.
  • the method further includes depositing at the introduction site, a plug member that contains a therepeutic agent that is released from the plug member to the target area.
  • the present invention additionally provides a method for sustaining the delivery of cells
  • the method involves introducing cells through an introduction site of a target area and delivering the cells to the target area.
  • the method further includes applying an energy stimulus to the target area that promotes a wound-healing response in the target area.
  • the present invention provides a method of sustaining the delivery of cells to a target area within a mammalian body by depositing at the site through which the cells are introduced (also referred to
  • the introduction site a plug member containing a therapeutic agent.
  • the therapeutic agent is released to the target area and acts to generally increase intracellular coupling between the target area and the grafted cells.
  • the target area may include any area of the body that is capable of accepting a cellular graft including for example, a tissue, an organ, or a blood vessel. Because the plug member is deposited at the site of cell introduction site, the plug member also inhibits cells from leaking from the introduction site into surrounding parts of the body and thereby prevents or precludes the need for repeated injection of cells to ensure effective and sustained treatment.
  • fibroblasts include, but are not limited to, normal or genetically modified mesenchymal stem cells, hematopoietic stem cells, progenitor cells, cardiomyocytes, myoblasts, procardiomyocytes, skeletal fibroblasts, and pericytes.
  • the type of cells selected for delivery will generally depend on the nature of the target area. For example, if the target area is a myopathic muscle, then myogenic cells maybe used; if the target area is cartilage, then chondrocytes or fibroblasts may
  • cardiomyoctes or skelatal myoblasts may be used.
  • the cells used in the present invention can be obtained or isolated from any
  • the recipient (homologous), or from a donor of a different species as the recipient (heterologous).
  • cells may be obtained from a tissue biopsy from one of the above-mentioned
  • sources and the tissue biopsy may be digested with collagenase or trypsin, for example, to
  • the cells may be obtained from bone marrow or peripheral
  • the cells may also be obtained from established cell lines or from embryonic cell
  • the cells useful in the present invention may be delivered to the target area via any
  • needles include needle injection catheters, hypodermic needles, biopsy needes, ablation catheters, cannulas and any other type of medically useful needle. Examples of non-needle injection direct
  • TMR transmural myocardial revascularization
  • PMR percutaneous myocardial revascularization
  • the plug member according to the present invention comprises a biocompatible member
  • the target area may comprise any protein, pharmaceutically active compound, nucleic acid
  • tRNA peptide, polypeptide, lipid, carbohydrate, small molecule, hormone, coenzyme and
  • metabolite amino acid, virus, metal including an organic and organometallic compound and salts thereof, polymer, or any combination thereof that operates to enhance the efficiency of cell delivery and/or increase the effectiveness of cell engraftment, survival, adhesion, division, or any combination thereof.
  • survival rate of cells is low subsequent to cellular
  • the therapeutic agent may be an agent that functions to prevent apoptosis or increase
  • the therapeutic agent comprises an agent that increases cell engraftment efficiency and cell
  • Non-limiting examples of such an agent include integrms, N-cadherin, and connexin- 43.
  • the therapeutic agent may also include any substance that increases the survival of cells and promotes cell engraftment, for example, by increasing cell division or promoting angiogenesis.
  • Non-limiting examples of such agents include growth factors such as vascular endothelial growth factor, hepatocyte growth factor, epidermal growth factor, transforming growth factor ⁇ and ⁇ 2 , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor alpha, insulin growth factor and acidic and basis fibroblast growth factor; and angiopoietins such as H1F1, Dell, PR39, or NF-kB.
  • the therapeutic agent may also include substances that suppress inflammation or an immune response such as
  • cytokines such as interleukins and lymphokines.
  • the type of therapeutic agent to be released also depends on the type of cells delivered to the target area and the desired outcomes of the cell transplantation. For example, if the target area is nerve tissue and nerve cells and support cell are injected into the nerve tissue, then the therapeutic agent may comprise nerve growth factor. If the target area is bone or connective tissue and osteocytes and periosteal cells are injected to the
  • the therapeutic agent may comprise insulin-growth factor or bone
  • growth factor such as BMP-7, BMP-2, BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-
  • the plug member may be fabricated of
  • the plug member may be a non-polymeric material or, preferably a polymeric material.
  • the plug member may be any suitable material or, preferably a polymeric material.
  • the plug member may be any suitable material or, preferably a polymeric material.
  • the plug member may be any suitable material or, preferably a polymeric material.
  • the plug member may be fabricated of any material capable of delivering a therapeutic agent to a target area and capable of sealing the introduction site so as to inhibit or prevent cell leakage.
  • the plug member may be composed of biodegradable polymers such as, for example, ethylene vinyl acetate, polyanhydrides, polyglycolic.
  • bioabsorbable and biostable polymers and copolymers are bioabsorbable and biostable polymers and copolymers.
  • biodegradable is meant that the material of the plug member will degrade over time by the action of enzymes, by simple or enzymatically catalyzed hydrolytic action and/or by other similar mechanisms in the human body.
  • bioabsorbable is meant that the material of the
  • plug member will be broken down and absorbed within the human body, for example, by a cell, a
  • the plug member may also be made of non-biodegradable materials such silicons,
  • glasses silicone elastomers.
  • Further examples include sintered hydroxyapatite, bioglass and
  • aluminates for example.
  • the plug member is composed of a non-polymeric material that is
  • the organic solvent is biocompatible and will at least one organic solvent.
  • the organic solvent has a
  • the solvent is capable of
  • fluid of the target area such as blood serum, lymph, cerebral spinal fluid (CSF), saliva, and the
  • Solvents that are useful include, for example, substituted heterocyclic compounds such as
  • NMP N-methyl-2-pyrrolidone
  • 2-pyrrolidone (2-pyrol) 2-pyrrolidone
  • alcohols such as propylene carbonate, ethylene carbonate and dimethyl carbonate; fatty acids such as acetic acid, lactic acid and heptanoic acid; alkyl esters of mono-, di-, and tricarboxylic
  • acids such as 2-ethyoxyethyl acetate, ethyl acetate, methyl acetate, ethyl lactate, ethyl butyrate,
  • citrate acetyl tributyl citrate, glyceryl triacetate; alkyl ketones such as acetone and methyl ethyl
  • ketone ether alcohols such as 2-ethoxyethanol, ethylene glycol dimethyl ether, glycofurol and
  • glycerol formal alcohols such as ethanol and propanol; polyhydroxy alcohols such as propylene glycol, polyethylene glycol (PEG), glycerin (glycerol), 1,3-butyleneglycol, and isopropylidene
  • alcohols such as ethanol and propanol
  • polyhydroxy alcohols such as propylene glycol, polyethylene glycol (PEG), glycerin (glycerol), 1,3-butyleneglycol, and isopropylidene
  • dialkylamides such as dimethylformamide and dimethylacetamide
  • dimethylsulfoxide dimethylsulfoxide
  • DMSO dimethylsulfone
  • tetrahydrofuran lactones such as e-caprolactone
  • butyrolactone cyclic alkyl amides such as caprolactam; aromatic amides such as
  • Preferred solvents include N-methyl-2-pyrrolidone, 2-pyrrolidone,
  • the organic solvent is non-toxic.
  • a composition of the non-polymeric material is preferably flowable with a consistency
  • the non-polymeric composition can be manipulated and shaped
  • the moldability of the composition as it hardens allows it to conform to irregularities, crevices, cracks, holes, and the like, in the
  • the resulting substantially solid matrix is preferably
  • biodegradable, bioabsorbable, and/or bioerodible will be gradually absorbed into the
  • bioerodible is meant that the plug member will erode or degrade over
  • composition of non-polymeric material of this embodiment can be any composition of non-polymeric material of this embodiment.
  • thermoplastic polymer such as
  • a polylactide, polycaprolactone, polyglycolide, or copolymer thereof to provide a more coherent solid plug member or a composition with greater viscosity so as to hold the plug member in place
  • non-polymeric materials are also capable of coagulating or solidifying to
  • the solid plug member has a firm consistency ranging from gelatinous to
  • present invention generally include any having the foregoing characteristics. Examples of useful
  • non-polymeric materials include sterols such as cholesterol, stigmasterol, ⁇ -sitosterol, and
  • estradiol cholesteryl esters such as cholesteryl stearate; C 12 -C 24 fatty acids such as lauric acid,
  • C lg -C 36 mono-, di- and triacylglycerides such as glyceryl monooleate, glyceryl monolinoleate, glyceryl
  • sucrose fatty acid esters such as sucrose distearate and sucrose palmitate
  • sorbitan fatty acid esters such as sucrose distearate and sucrose palmitate
  • acid esters such as sorbitan monostearate, sorbitan monopalmitate and sorbitan tristearate;
  • C 16 -C I8 fatty alcohols such as cetyl alcohol, myristyl alcohol, stearyl alcohol, and cetostearyl
  • esters of fatty alcohols and fatty acids such as cetyl palmitate and cetearyl palmitate;
  • anhydrides of fatty acids such as stearic anhydride
  • phosphohpids including phosphatidylcholme
  • lysoderivatives thereof sphingosine and derivatives thereof; spingomyelins such as stearyl,
  • palmitoyl and tricosanyl spingomyelins
  • ceramides such as stearyl and palmitoyl ceramides
  • glycosphingolipids lanolin and lanolin alcohols
  • combinations and mixtures thereof
  • Preferred non-polymeric materials include cholesterol, glyceryl monostearate, glycerol tristearate,
  • composition of the plug member may depend on
  • the plug member may be pre-formed prior to use or formed by in situ phase change or
  • the plug member is heated (or cooled, depending on
  • a temperature sensitive polymer which is
  • liquid at above or below physiological temperature i.e. about 37 °C
  • suitable materials for use in this embodiment include N-isopropylacrylamide and certain celluloses.
  • the plug member is applied to the introduction site while the
  • plug member is in a first fluent state. Then the plug member is maintained in a position so as to
  • the conversion may be achieved cither by changing
  • state or essentially non-fluent state may be the result of a phase change, viscosity change, or polymerization.
  • plug member is formed by in situ polymerization or phase
  • the plug member is fabricated of a polymer that can be polymerized or have its viscosity
  • Non-limiting examples of such polymers that alter viscosity as a function of temperature include poly(oxyalkene) polymers and copolymers such as poly(ethylene oxide) -poly(propylene oxide) copolymers, and copolymers and blends of these polymers with polymers such as poly(alpha-hydroxy) acids, including but not limited to lactic, glycolic, and hydroxybutyric acids, polycarprolactones, and polyvalerolactones.
  • Examples of polymers that polymerize in the presence of divalent ions such as calcium, barium, magnesium, copper, and iron include naturally occurring polymers collagen, fibrin, elastin, agarose, agar, polysaccharides such as hyaluronic acid, hyalobiuronic acid, heparin, cellulose, alginate, curdlan, chitin, and chitosan, and derivatives thereof, cellulose acetate, carboxymethyl cellulose, hydroxymethyl cellulose, cellulose sulfate sodium salt, and ethylcellulose.
  • divalent ions such as calcium, barium, magnesium, copper, and iron
  • radiation generally include those polymers that contain a double-bond or a triple-bond.
  • examples of such polymers include monomers that are polymerized into poly(acrilic acids), poly(acrylates), polyacrylamides, polyvinyl alcohols, polyethylene glycols, and ethylene vinyl acetates.
  • the release rate of the therapeutic agent may be controlled by the particular composition of the plug member.
  • the plug member is made of polymeric material
  • the amount, concentration, and type of polymer can be controlled by the amount, concentration, and type of polymer.
  • the release of agents contained in a biodegradable plug can be controlled by the rate of degradation of the plug member.
  • the plug member is fabricated to provide for
  • the plug member maybe
  • SD3S styrene isobutylene styrene
  • the release rate of the therapeutic agent may also be adjusted by modifying various properties of the plug member as well as by adjusting the properties of the therapeutic agent relative to the plug member. These properties include the porosity of the plug member, which maybe affected by adjusting the
  • the properties also include the size, shape, dosage form, and quantity of the therapeutic agent.
  • the size of the plug member should preferably be such that the plug member can
  • the size of the plug member will therefore vary depending on the mode of administration. For example, if cells are delivered to the target site via a needle, then the diameter of the plug member should at least substantially correspond to the diameter of the needle in order to properly seal the opening created by the needle at the introduction site.
  • the plug member may also be deposited at the introduction site by any suitable means of administration such as, for example, direct injection via a needle or catheter and may be deposited after or during cell delivery.
  • the plug members may also be delivered through a lumen of a multi-lumen catheter, in which case the cells are
  • the plug member may optionally include a bioadhesive that is released to the target area.
  • Bioadhesive material maybe any biocompatible additive that results in an increase of the affinity
  • suitable bioadhesive materials include fibrinogen, with or without thrombin, fibrin, fibropectin, elastin, laminin, cyanoacrylates, polyacrylic acid, polystyrene, bioabsorbable
  • biostable polymers derivitized with sticky molecules such as arginine, glycine, and aspartic
  • the cells are delivered to the target area and a plug member is subsequently or concurrently deposited at the site of introduction.
  • cells and plug member may be introduced and delivered through the same instrument or different
  • the cells may be introduced and delivered via an injection needle and
  • the plug member may then be deposited via a
  • a dual-lumen catheter may be
  • the plug member releases therapeutic agents in the target area that act to
  • the plug member is used to regulate the expression of biomolecules by delivered cells.
  • biomolecules include any substance that enhances the expression of biomolecules by delivered cells.
  • biomolecules include for example, proteins
  • polysaccharides oligopeptides; polypeptides; oligonucleotides and polynucleotides (e.g., DNA,
  • cDNA dsDNA, ssDNA
  • aminio acids nucleotides
  • lipids lipids
  • carbohydrates lipids
  • hormones hormones
  • coenzymes and specifically growth factors; cytokines; and pharmaceutically active compounds,
  • the cells may be genetically transformed prior to delivery to the target area in
  • the cells with genes encoding the biomolecule of interest.
  • the cells maybe transfected using any combination of viruses, viruses, and viruses.
  • the vector includes
  • the desired gene operably linked to a inducible promoter, which yields expression of the gene in the cells into which it is delivered after being activated by an inducing agent.
  • inducible promoter and corresponding suitable inducing agent is contemplated by the present
  • Exemplary inducible promoters include sheep metallothiomne (MT) promoter, mouse
  • MMTV mammary tumor virus
  • Inducible promoters can be general
  • inducible promoters yielding expression in a variety of mammalian cells, or cell specific, or even nuclear versus cytoplasmic specific.
  • agents include, glucocorticoids such as dexamethasone for the MMTV promoter, or a metal such
  • inducible promoter is activated by the inducing agent, the expresson of the desired gene is
  • an anti-apoptic gene of the tranfected delivered cells is no longer expressed.
  • an anti-apoptic gene for example, an anti-apoptic gene
  • the cells may also be transformed to
  • a prodrug contained within the plug member express at least one enzyme which reacts with a prodrug contained within the plug member.
  • prodrug is generally defined as an inactive derivative of a drug molecule that requires a
  • the transformed cells are delivered to the target area and concurrently
  • the plug member containing the prodrug is deposited at the introduction site and
  • the prodrug is released to the target area.
  • the enzyme expressed by the cells is expressed by the cells
  • the active prodrug' can possess
  • the application of an energy stimulus may be used in
  • the energy stimulus may also seal the
  • introduction site by sealing the open ends of the tissue that characterize the introduction site.
  • energy stimuli include ultrasound, lasers, radio-frequency, electrical current, or heating.
  • the introduction site is sealed by performing radio frequency cautery at the introduction site to seal the introduction site.
  • Cauterization involves using such intense heat to seal the open ends of the tissue.
  • Radio frequency cautery may be performed by any suitable method known to those skilled in the art.
  • the introduction site is sealed by performing laser heating at the introduction site to seal the introduction site.
  • laser emitted optical energy may be used to heat biological tissue to a degree suitable for denaturing the tissue proteins such that the collagenous elements of the tissue form a "biological glue" to seal the target area.
  • Suitable methods of laser heating a tissue are known to those of skill in the art.
  • the energy stimulus may be used in conjunction with cell delivery alone or may be used in conjunction with cell delivery and plug member deposit to complement the effect of the therapeutic agent released by the plug member.
  • cells may be delivered to the target area, an energy stimuli may be applied to the target area, and, optionally, a plug member containing a therapeutic agent maybe deposited at the introduction site, wherein the therapeutic agent is released to the target area.
  • the present invention is not limited to any particular order of these steps and the energy stimulus maybe applied concurrent or subsequent to cell delivery and the plug member may be deposited concurrent or subsequent to application of the energy stimuli.
  • injected in vivo or ex vivo including, for example, heart, lung, brain, liver, skeletal muscle, smooth muscle, kidney, bladder, intestines, stomach, pancreas, ovary, prostrate, eye, tuorms, cartilage, bone, and skin.
  • disorders include, but are not limited to, angiogenic diseases, heart failure, myocardial ischemia, angina pectoris, myocardial infarction, stroke, amyotrophic lateral sclerosis (ALS), myastenia gravis, Eaton-Lambert Syndrome, muscular dystrophies, Parkinson's disease, Alzheimer's disease, type 1 diabetes or insulin-requiring type 2 diabetes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé permettant de maintenir un transfert direct de cellules dans une zone cible. Le procédé de l'invention consiste généralement à transférer des cellules dans une zone cible. En particulier, les cellules sont introduites via un site d'introduction d'une zone cible et sont transférées dans la zone cible. Le procédé consiste en outre à déposer sur le site d'introduction un élément d'obturation contenant un agent thérapeutique qui sert généralement à augmenter le couplage intracellulaire entre les cellules greffées et la zone cible. L'élément d'obturation sert également à fermer le site d'introduction afin d'empêcher que les cellules s'échappent du site d'introduction jusque dans les zones corporelles environnantes.
PCT/US2003/021421 2002-07-12 2003-07-09 Procede permettant de maintenir un transfert cellulaire direct Ceased WO2004006942A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03764400A EP1523319A1 (fr) 2002-07-12 2003-07-09 Procede permettant de maintenir un transfert cellulaire direct
AU2003251813A AU2003251813A1 (en) 2002-07-12 2003-07-09 Method for sustaining direct cell delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/193,124 2002-07-12
US10/193,124 US20040009155A1 (en) 2002-07-12 2002-07-12 Method for sustaining direct cell delivery

Publications (1)

Publication Number Publication Date
WO2004006942A1 true WO2004006942A1 (fr) 2004-01-22

Family

ID=30114469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021421 Ceased WO2004006942A1 (fr) 2002-07-12 2003-07-09 Procede permettant de maintenir un transfert cellulaire direct

Country Status (4)

Country Link
US (1) US20040009155A1 (fr)
EP (1) EP1523319A1 (fr)
AU (1) AU2003251813A1 (fr)
WO (1) WO2004006942A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093044A1 (fr) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Cellules souches mesenchymateuses et leurs utilisations

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956280B2 (en) 2002-05-30 2015-02-17 Intuitive Surgical Operations, Inc. Apparatus and methods for placing leads using direct visualization
US20050228452A1 (en) * 2004-02-11 2005-10-13 Mourlas Nicholas J Steerable catheters and methods for using them
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
US20070093748A1 (en) * 2005-06-23 2007-04-26 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
US20070172472A1 (en) * 2005-06-23 2007-07-26 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
US20080033241A1 (en) * 2006-08-01 2008-02-07 Ruey-Feng Peh Left atrial appendage closure
EP2091569A4 (fr) 2006-10-31 2011-09-14 Univ Rochester Administration ciblee d'agents therapeutiques au moyen de matrices lyophilisees
US9468364B2 (en) 2008-11-14 2016-10-18 Intuitive Surgical Operations, Inc. Intravascular catheter with hood and image processing systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055252A1 (fr) * 1998-04-24 1999-11-04 University Of Massachusetts Developpement et support guides de compositions de cellules et d'hydrogel
WO2002030481A1 (fr) * 2000-10-10 2002-04-18 Massachusetts Institute Of Technology Liberation de cellules utilisant des structures gel en maille degradables de maniere controlable
WO2002072113A1 (fr) * 2001-03-09 2002-09-19 Intercytex Limited Guerison d'une plaie au moyen de fibroblastes
WO2003024297A2 (fr) * 2001-09-14 2003-03-27 The Research Foundation Of State University Of New York Systeme de stockage et de distribution de cellules

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32208E (en) * 1982-11-16 1986-07-15 Ethicon, Inc. Absorbable hemostatic composition
US4890612A (en) * 1987-02-17 1990-01-02 Kensey Nash Corporation Device for sealing percutaneous puncture in a vessel
US5538722A (en) * 1989-06-13 1996-07-23 Stanford University Isolation, growth, differentiation and genetic engineering of human muscle cells
US5725522A (en) * 1990-06-15 1998-03-10 Rare Earth Medical, Inc. Laser suturing of biological materials
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
US5326350A (en) * 1992-05-11 1994-07-05 Li Shu Tung Soft tissue closure systems
US5681873A (en) * 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US6015671A (en) * 1995-06-07 2000-01-18 Indiana University Foundation Myocardial grafts and cellular compositions
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US5840059A (en) * 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
US5693029A (en) * 1995-07-10 1997-12-02 World Medical Manufacturing Corporation Pro-cell intra-cavity therapeutic agent delivery device
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6159232A (en) * 1997-12-16 2000-12-12 Closys Corporation Clotting cascade initiating apparatus and methods of use and methods of closing wounds
US6605294B2 (en) * 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US6554851B1 (en) * 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
DE10037530A1 (de) * 1999-08-31 2001-03-22 Ntn Toyo Bearing Co Ltd Dichtungsvorrichtung für Lager

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055252A1 (fr) * 1998-04-24 1999-11-04 University Of Massachusetts Developpement et support guides de compositions de cellules et d'hydrogel
WO2002030481A1 (fr) * 2000-10-10 2002-04-18 Massachusetts Institute Of Technology Liberation de cellules utilisant des structures gel en maille degradables de maniere controlable
WO2002072113A1 (fr) * 2001-03-09 2002-09-19 Intercytex Limited Guerison d'une plaie au moyen de fibroblastes
WO2003024297A2 (fr) * 2001-09-14 2003-03-27 The Research Foundation Of State University Of New York Systeme de stockage et de distribution de cellules

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005093044A1 (fr) 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Cellules souches mesenchymateuses et leurs utilisations
EP1727892A4 (fr) * 2004-03-22 2007-08-22 Osiris Therapeutics Inc Cellules souches mesenchymateuses et leurs utilisations
EP2298863A3 (fr) * 2004-03-22 2011-04-13 Osiris Therapeutics, Inc. Cellules souches mésenchymateuses et utilisations associées
EP2298862A3 (fr) * 2004-03-22 2011-08-24 Osiris Therapeutics, Inc. Cellules souches mésenchymateuses et utilisations associées
EP2298864A3 (fr) * 2004-03-22 2011-11-23 Osiris Therapeutics, Inc. Cellules souches mésenchymateuses et utilisations associées
EP2298861A3 (fr) * 2004-03-22 2011-11-30 Osiris Therapeutics, Inc. Cellules souches mésenchymateuses et utilisations associées
EP2298863B1 (fr) 2004-03-22 2015-07-22 Mesoblast International Sàrl Cellules souches mésenchymateuses et utilisations associées
US9694035B2 (en) 2004-03-22 2017-07-04 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
US9943547B2 (en) 2004-03-22 2018-04-17 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US10668101B2 (en) 2004-03-22 2020-06-02 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10716814B2 (en) 2004-03-22 2020-07-21 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US10729727B2 (en) 2004-03-22 2020-08-04 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10828334B1 (en) 2004-03-22 2020-11-10 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US10960025B2 (en) 2004-03-22 2021-03-30 Mesoblast International Sárl Mesenchymal stem cells and uses therefor
US11389484B2 (en) 2004-03-22 2022-07-19 Mesoblast International Sárl Mesenchymal stem cells and uses therefor

Also Published As

Publication number Publication date
EP1523319A1 (fr) 2005-04-20
AU2003251813A1 (en) 2004-02-02
US20040009155A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
US6554851B1 (en) Methods of sealing an injection site
US7070582B2 (en) Injection devices that provide reduced outflow of therapeutic agents and methods of delivering therapeutic agents
Zhang et al. Microneedle system for tissue engineering and regenerative medicine
Griffith Polymeric biomaterials
US7674250B2 (en) Methods of delivering therapeutic agents
KR101865689B1 (ko) 부프레노르핀을 포함하는 주입가능한 유동성 조성물
JP2012507562A (ja) 微小球性多孔質生体適合性足場並びにその製造方法及び装置
JP2005510454A (ja) マイクロ粒子による治療薬の保護
US20120063997A1 (en) Delivery system with scaffolds
Bae et al. Emerging hydrogel designs for controlled protein delivery
US20090186077A1 (en) Thermo-responsive materials
Li et al. Multifunctional hydrogel-based engineered extracellular vesicles delivery for complicated wound healing
US20040009155A1 (en) Method for sustaining direct cell delivery
Minehan et al. Controlled release of therapeutics from enzyme-responsive biomaterials
Yu Application of hydrogels in cardiac regeneration
Cheng et al. Multifunctional Microneedle Patches for Perivascular Gene Delivery and Treatment of Vascular Intimal Hyperplasia
CN113195034A (zh) 基于微细结构体的药物注入装置及其制造方法
KR101898816B1 (ko) 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템
CN112022797A (zh) 温度敏感型等离子体活性生物胶制备方法及活性生物胶
Yi et al. A novel, biodegradable, thermoresponsive hydrogel attenuates ventricular remodeling and improves cardiac function following myocardial infarction-a review
AU2016330924A1 (en) Compositions for an injectable, in situ forming neuroscaffold and methods of using the same
Wang et al. Dermal Fibrosis and the Current Scope of Hydrogel Strategies for Scarless Wound Healing
WO2009148583A2 (fr) Procédé pour l'amélioration de la biodisponibilité de l'octréotide
Nazir et al. Smart bioactive hydrogels for myocardial infarction repair: a multifunctional approach integrating stimuli-responsive drug delivery, electroconductivity, and real-time biosensing
JP6302936B2 (ja) 心臓保護のための方法及び医薬組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003764400

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003764400

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP